Inhibitory peptide analogs derived from a major uveitogenic epitope protect from antiretinal autoimmunity by inducing type 2 and regulatory T cells

Journal of Leukocyte Biology

Volumn 84, Issue 2, 2008, Pages 577-585

  Cortes, Lizette M ^a   Avichezer, Dody ^a   Silver, Phyllis B ^a   Luger, Dror ^a   Mattapallil, Mary J ^a   Chan, Chi Chao ^a   Caspi, Rachel R ^a  

^a NATIONAL EYE INSTITUTE   (United States)

Author keywords

Experimental autoimmune uveitis; Tolerance

Indexed keywords

ALANINE; ALANYLGLYCYLISOLEUCYLPROLYLTYROSYLVALYLISOLEUCYLSERYL TYROSYLLEUCYLHISTIDYLPROLYLGLYCYLASPARAGINYLTHREONYLVALYL METHIONYLHISTIDYLVALYLASPARTIC ACID; ANTIGEN; CYTOKINE; EPITOPE; GAMMA INTERFERON; IMMUNOGLOBULIN G1; IMMUNOGLOBULIN G2A; IMMUNOMODULATING AGENT; INTERLEUKIN 10; INTERLEUKIN 13; INTERLEUKIN 17; INTERLEUKIN 4; INTERLEUKIN 5; INTERPHOTORECEPTOR RETINOID BINDING PROTEIN; PEPTIDE DERIVATIVE; RETINA ANTIGEN; SERYLALANYLISOLEUCYLPROLYLTYROSYLVALYLISOLEUCYLSERYL TYROSYLLEUCYLHISTIDYLPROLYLGLYCYLASPARAGINYLTHREONYLVALYL METHIONYLHISTIDYLVALYLASPARTIC ACID; SERYLGLYCYLALANYLPROLYLTYROSYLVALYLISOLEUCYLSERYLTYROSYLLEUCYL HISTIDYLPROLYLGLYCYLASPARAGINYLTHREONYLVALYLMETHIONYLHISTIDYLVALYLASPARTIC ACID; SERYLGLYCYLISOLEUCYLALANYLTYROSYLVALYLISOLEUCYLSERYLTYROSYL LEUCYLHISTIDYLPROLYLGLYCYLASPARAGINYLTHREONYLVALYLMETHIONYLHISTIDYLVALYL ASPARTI C ACID; SERYLGLYCYLISOLEUCYLPROLYLALANYLVALYLISOLEUCYLSERYLTYROSYLLEUCYL HISTIDYLPROLYLGLYCYLASPARAGINYLTHREONYLVALYLMETHIONYLHISTIDYLVALYLASPARTIC ACID; SERYLGLYCYLISOLEUCYLPROLYLTYROSYLALANYLISOLEUCYLSERYLTYROSYLLEUCYL HISTIDYLPROLYLGLYCYLASPARAGINYLTHREONYLVALYLMETHIONYLHISTIDYLVALYLASPARTIC ACID; SERYLGLYCYLISOLEUCYLPROLYLTYROSYLVALYLALANYLSERYLTYROSYLLEUCYL HISTIDYLPROLYLGLYCYLASPARAGINYLTHREONYLVALYLMETHIONYLHISTIDYLVALYLASPARTIC ACID; SERYLGLYCYLISOLEUCYLPROLYLTYROSYLVALYLISOLEUCYLALANYLTYROSYL LEUCYLHISTIDYLPROLYLGLYCYLASPARAGINYLTHREONYLVALYLMETHIONYLHISTIDYLVALYL ASPARTI C ACID; SERYLGLYCYLISOLEUCYLPROLYLTYROSYLVALYLISOLEUCYLSERYLALANYLLEUCYL HISTIDYLPROLYLGLYCYLASPARAGINYLTHREONYLVALYLMETHIONYLHISTIDYLVALYLASPARTIC ACID; SERYLGLYCYLISOLEUCYLPROLYLTYROSYLVALYLISOLEUCYLSERYLTYROSYL LEUCYLALANYLPROLYLGLYCYLASPARAGINYLTHREONYLVALYLMETHIONYLHISTIDYLVALYLASPARTIC ACID; SERYLGLYCYLISOLEUCYLPROLYLTYROSYLVALYLISOLEUCYLSERYLTYROSYL LEUCYLHISTIDYLALANYLGLYCYLASPARAGINYLTHREONYLVALYLMETHIONYL HISTIDYLVALYLASPARTI C ACID; SERYLGLYCYLISOLEUCYLPROLYLTYROSYLVALYLISOLEUCYLSERYLTYROSYLALANYL HISTIDYLPROLYLGLYCYLASPARAGINYLTHREONYLVALYLMETHIONYLHISTIDYLVALYLASPARTIC ACID; SERYLGLYCYLISOLEUCYLPROLYLTYROSYLVALYLISOLEUCYLSERYLTYROSYLLEUCYL HISTIDYLPROLYLALANYLASPARAGINYLTHREONYLVALYLMETHIONYLHISTIDYLVALYLASPARTIC ACID; UNINDEXED DRUG;

ADOPTIVE IMMUNOTHERAPY; AMINO ACID SEQUENCE; AMINO ACID SUBSTITUTION; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY BLOOD LEVEL; ANTIBODY TITER; ANTIGEN SPECIFICITY; ARTICLE; AUTOIMMUNE DISEASE; CELLULAR IMMUNITY; CONTROLLED STUDY; CROSS REACTION; DONOR; DRUG ACTIVITY; DRUG EFFECT; DRUG IDENTIFICATION; DRUG MECHANISM; DRUG SYNTHESIS; EFFECTOR CELL; EXPERIMENTAL MOUSE; HYPERSENSITIVITY; IMMUNE RESPONSE; IMMUNIZATION; IMMUNOGENICITY; LYMPHOCYTE PROLIFERATION; LYMPHOID CELL; MOUSE; NONHUMAN; PATHOGENICITY; PRIORITY JOURNAL; RECIPIENT; REGULATORY T LYMPHOCYTE; SPLEEN CELL; TH2 CELL; UVEITIS;

ADOPTIVE TRANSFER; AMINO ACID SEQUENCE; ANIMALS; AUTOIMMUNE DISEASES; AUTOIMMUNITY; CYTOKINES; IMMUNE TOLERANCE; LYMPHOCYTE ACTIVATION; MICE; MODELS, ANIMAL; MOLECULAR SEQUENCE DATA; PEPTIDES; RETINA; STRUCTURE-ACTIVITY RELATIONSHIP; T-LYMPHOCYTES, REGULATORY; UVEITIS;

MURINAE; MUS;

EID: 48649107859     PISSN: 07415400     EISSN: None     Source Type: Journal    
DOI: 10.1189/jlb.0308189     Document Type: Article

References (26)

1. Caspi, R. R. (1999) Immune mechanisms in uveitis. Springer Semin. Immunopathol. 21, 113-124.
2. Caspi, R. R., Roberge, F. G., McAllister, C. G., el-Saied, M., Kuwabara, T., Gery, I., Hanna, E., Nussenblatt, R. B. (1986) T cell lines mediating experimental autoimmune uveoretinitis (EAU) in the rat. J. Immunol. 136, 928-933.
3. Agarwal, R. K., Caspi, R. R. (2004) Rodent models of experimental autoimmune uveitis. Methods Mol. Med. 102, 395-419.
4. Silver, P. B., Rizzo, L. V., Chan, C. C., Donoso, L. A., Wiggert, B., Caspi, R. R. (1995) Identification of a major pathogenic epitope in the human IRBP molecule recognized by mice of the H-2r haplotype. Invest. Ophthalmol. Vis. Sci. 36, 946-954.
5. Whitcup, S. M., Nussenblatt, R. B. (1997) Immunologic mechanisms of uveitis. New targets for immunomodulation. Arch. Ophthalmol. 115, 520-525.
6. Caspi, R. R. (2003) Regulation, counter-regulation, and immunotherapy of autoimmune responses to immunologically privileged retinal antigens. Immunol. Res. 27, 149-160.
7. Arnon, R., Aharoni, R. (2004) Mechanism of action of glatiramer acetate in multiple sclerosis and its potential for the development of new applications. Proc. Natl. Acad. Sci. USA 101 (Suppl. 2), 14593-14598.
8. Sela, M., Mozes, E. (2004) Therapeutic vaccines in autoimmunity. Proc. Natl. Acad. Sci. USA 101 (Suppl. 2), 14586-14592.
9. Fontoura, P., Garren, H., Steinman, L. (2005) Antigen-specific therapies in multiple sclerosis: going beyond proteins and peptides. Int. Rev. Immunol. 24, 415-446.
10. Dayan, M., Sthoeger, Z., Neiman, A., Abarbanel, J., Sela, M., Mozes, E. (2004) Immunomodulation by a dual altered peptide ligand of autoreactive responses to the acetylcholine receptor of peripheral blood lymphocytes of patients with myasthenia gravis. Hum. Immunol. 65, 571-577.
11. Illes, Z., Waldner, H., Reddy, J., Bettelli, E., Nicholson, L. B., Kuchroo, V. K. (2005) T cell tolerance induced by cross-reactive TCR ligands can be broken by superagonist resulting in anti-inflammatory T cell cytokine production. J. Immunol. 175, 1491-1497.
12. Caspi, R. R. (2003) Experimental autoimmune uveoretinitis (EAU) - mouse and rat. In Current Protocols in Immunology (J. E. Coligan, A. M. Kruisbeek, D. H. Margulies, E. M. Shevech, W. Strober, eds.), vol. 15.6, New York, NY; San Diego, CA, USA.
13. Cortes, L. M., Mattapallil, M. J., Silver, P. B., Donoso, L. A., Liou, G. I., Zhu, W., Chan, C-C., Caspi, R. R. (2008) Repertoire analysis and new pathogenic epitopes of IRBP in C57BL/6 (H-2b) and B10.RIII (H-2r) mice. Invest. Ophthalmol. Vis. Sci. 49, 1946-1956.
14. Caspi, R. R., Roberge, F. G., Chan, C. C., Wiggert, B., Chader, G. J., Rozenszajn, L. A., Lando, Z., Nussenblatt, R. B. (1988) A new model of autoimmune disease. Experimental autoimmune uveoretinitis induced in mice with two different retinal antigens. J. Immunol. 140, 1490-1495.
15. Rizzo, L. V., DeKruyff, R. H., Umetsu, D. T., Caspi, R. R. (1995) Regulation of the interaction between Th1 and Th2 T cell clones to provide help for antibody production in vivo. Eur. J. Immunol. 25, 708-716.
16. Rizzo, L. V., Silver, P., Wiggert, B., Hakim, F., Gazzinelli, R. T., Chan, C. C., Caspi, R. R. (1996) Establishment and characterization of a murine CD4+ T cell line and clone that induce experimental autoimmune uveoretinitis in B10.A mice. J. Immunol. 156, 1654-1660.
17. Snedecor, G. W., Cochran, W. G. (1967) Statistical Methods, Ames, IA, USA, Iowa State University Press.
18. Young, D. A., Lowe, L. D., Booth, S. S., Whitters, M. J., Nicholson, L., Kuchroo, V. K., Collins, M. (2000) IL-4, IL-10, IL-13, and TGF-β from an altered peptide ligand-specific Th2 cell clone down-regulate adoptive transfer of experimental autoimmune encephalomyelitis. J. Immunol. 164, 3563-3572.
19. Bielekova, B., Goodwin, B., Richert, N., Cortese, I., Kondo, T., Afshar, G., Gran, B., Eaton, J., Antel, J., Frank, J. A., McFarland, H. F., Martin, R. (2000) Encephalitogenic potential of the myelin basic protein peptide (amino acids 83-99) in multiple sclerosis: results of a phase II clinical trial with an altered peptide ligand. Nat. Med. 6, 1167-1175.
20. Kappos, L., Comi, G., Panitch, H., Oger, J., Antel, J., Conlon, P., Steinman, L. (2000) Induction of a non-encephalitogenic type 2 T helper-cell autoimmune response in multiple sclerosis after administration of an altered peptide ligand in a placebo-controlled, randomized phase II trial. The Altered Peptide Ligand in Relapsing MS Study Group. Nat. Med. 6, 1176-1182.
21. DeVoss, J., Hou, Y., Johannes, K., Lu, W., Liou, G. I., Rinn, J., Chang, H., Caspi, R. R., Fong, L., Anderson, M. S. (2006) Spontaneous autoimmunity prevented by thymic expression of a single self-antigen. J. Exp. Med. 203, 2727-2735.
22. Pennesi, G., Mattapallil, M. J., Sun, S. H., Avichezer, D., Silver, P. B., Karabekian, Z., David, C. S., Hargrave, P. A., McDowell, J. H., Smith, W. C., Wiggert, B., Donoso, L. A., Chan, C. C., Caspi, R. R. (2003) A humanized model of experimental autoimmune uveitis in HLA class II transgenic mice. J. Clin. Invest. 111, 1171-1180.
23. Nussenblatt, R. B., Whitcup, S. M. (2004) Uveitis: Fundamentals and Clinical Practice, Philadelphia, PA, USA, Mosby (Elsevier).
24. Silver, P. B., Agarwal, R. K., Su, S. B., Suffia, I., Grajewski, R. S., Luger, D., Chan, C. C., Mahdi, R. M., Nickerson, J. M., Caspi, R. R. (2007) Hydrodynamic vaccination with DNA encoding an immunologically privileged retinal antigen protects from autoimmunity through induction of regulatory T cells. J. Immunol. 179, 5146-5158.
25. Nussenblatt, R. B. (2002) Bench to bedside: new approaches to the immunotherapy of uveitic disease. Int. Rev. Immunol. 21, 273-289.
26. Vanderlugt, C. L., Miller, S. D. (2002) Epitope spreading in immune-mediated diseases: implications for immunotherapy. Nat. Rev. Immunol. 2, 85-95.